Loading stock data…
Takeda Pharmaceutical Company L (TAK)
$15.98+0.07 (+0.44%)
After Hours$15.67-0.31 (-1.94%)· Last close Jun 29
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $15.98 with a market capitalization of $50.5B. Wall Street consensus targets $20.57 (3 analysts), implying a +28.7% move over the next 12 months. The stock is currently 15% below its 52-week high of $18.90, remaining 0.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +28.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.09T↓ | $1.19T↑ | $1.11T↑ | $1.11T↑ | $1.05T |
| Gross Profit | $688.84B↓ | $790.55B↑ | $732.74B↑ | $722.01B↑ | $671.32B |
| Operating Income | $42.07B↓ | $168.82B↑ | $69.00B↓ | $184.56B↑ | $68.54B |
| Net Income | -$368.47B↓ | $103.64B↑ | -$11.80B↓ | $124.24B↑ | -$103.16B |
Peer Comparison
JNJUNHPFE
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therap...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.49B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.05%
Volume
Today's trading volume
3.54M
Recent News
Alkermes Faces Risk on Orexin-Related Value From Upcoming Updates, BofA Says
Alkermes (ALKS) stock has been re-rated following a recent orexin-peer takeout, but upcoming orexin
Alkermes’ incoming CEO has a plan to outplay Lilly and Takeda
Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an “orexin” market that analysts see as a multibillion-dollar opportunity.
Asian Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
Asian equities traded in the US as American depositary receipts fell Tuesday morning, tumbling 3.1%
Denali to Sell Priority Review Voucher for $195M Cash Boost
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Takeda (TSE:4502) Unveils Phase 3 Wins In Narcolepsy And Psoriasis
Takeda Pharmaceutical (TSE:4502) reported new Phase 3 results for oveporexton in narcolepsy type 1, indicating improvements in core symptoms and daily functioning. The company also released Phase 3 data for zasocitinib in moderate to severe plaque psoriasis, where the drug outperformed an established competitor. These late stage trial readouts highlight progress across sleep medicine and autoimmune conditions, with potential to reshape treatment options if approvals follow. TSE:4502 is...